Skip to main content

Madrigal Pharmaceuticals, Inc.

corporate_fare Company Profile

Madrigal Pharmaceuticals, Inc.

MDGL·NASDAQ·Life Sciences·CIK 0001157601

The company is a biopharmaceutical company focused on developing new treatments for metabolic dysfunction-associated steatohepatitis ("MASH"), a serious liver disease. MASH was previously known as nonalcoholic steatohepatitis ("NASH"). MASH is the leading cause of liver transplantation in women, the second leading cause of all liver transplantation in the United States, and the fastest-growing indication for liver transplantation in Europe. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta ("THR-β") agonist designed to target key underlying causes of MASH. In March 2024, Rezdiffra became the first therapy approved by the FDA for patients with MASH and was commercially available in the United States starting in April 2024. Following conditional marketing authorization ("CMA") from the European Commission ("EC"), the company launched Rezdiffra in Germany in September 2025. Rezdiffra was the first medication approved by both the FDA and EC for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3 fibrosis). The company is also evaluating Rezdiffra in patients with compensated MASH cirrhosis (consistent with F4c fibrosis) in its MAESTRO-NASH OUTCOMES trial. Additionally, the company is developing a focused pipeline of MASH treatments. Through business development, it has acquired rights to MGL-2086, an oral glucagon-like peptide-1 ("GLP-1") receptor agonist, ervogastat, an oral diacylglycerol O-acyltransferase 2 ("DGAT2") inhibitor, six small interfering RNA ("siRNA") programs, and additional preclinical MASH candidates. For the year ended December 31, 2025, the company generated $958.4 million in product revenue from sales of Rezdiffra.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for MDGL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for MDGL spans 4, 10-Q, 8-K, DEF 14A.

Recent high-impact activity:

  • Baker Bros. Buys $35M of Madrigal Stock Days After First Profitable Quarter
  • One-Year Rezdiffra Data Shows Liver Stiffness Improvement in Up to 93% of Patients
  • Madrigal 10-Q Details First Profitable Quarter, $961.8M Cash, EPS Restatement and New SOX Suit
  • Madrigal Posts First Profitable Quarter as Rezdiffra Sales Hit $431.3M
  • Madrigal Posts $1.83 Third-Quarter EPS

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$958.4M
Net Income
-$288.28M
Diluted EPS
-$12.85
Op. Cash Flow
-$189.55M
Free Cash Flow
-$190.02M
Operating Income
-$300.1M
Cash & Equivalents
$198.69M
Total Debt
$339.88M
Debt / Equity
0.56×
Net Margin
-30.1%
Shares Outstanding
22.84M sh
Source: 10-K · filed 2026-02-19 · accession 0001628280-26-009514

Short Interest & Short Volume

7.64 days to cover

FINRA reported short interest of 2,136,404 shares in MDGL as of the October 30, 2026 settlement, a 2.6% decrease from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 39.4% of MDGL volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,136,404 shares as of October 30, 2026
Change vs prior period▼ 2.6%
Days to cover7.64 at avg daily volume of 279,558
Daily short volume (FINRA facilities)39.4% of 168,263 shares on November 20, 2026
5-day average short volume52.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with M →
$379.1
52-week range · as of 2026-11-06 $353.54 – $615
Market cap
$8.81B
Volume
327.8K (0.6× avg)
3-mo avg 521.2K
Live data · 2026-11-21 12:35 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MDGL - Latest Insights

MDGL
Nov 06, 2026, 5:30 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $399.93
Real-time Price: $379.10 info
Change: -$20.83 (-5%) info
Market Cap: $8.806B info
MDGL
Nov 05, 2026, 10:35 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $408.99
Real-time Price: $379.10 info
Change: -$29.89 (-7%) info
Market Cap: $8.806B info
MDGL
Nov 03, 2026, 9:10 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $428.01
Real-time Price: $379.10 info
Change: -$48.91 (-11%) info
Market Cap: $8.806B info
MDGL
Nov 03, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $477.00
Real-time Price: $379.10 info
Change: -$97.90 (-21%) info
Market Cap: $8.806B info
MDGL
Nov 03, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $431.16
Real-time Price: $379.10 info
Change: -$52.05 (-12%) info
Market Cap: $8.806B info
MDGL
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $475.00
Real-time Price: $379.10 info
Change: -$95.90 (-20%) info
Market Cap: $8.806B info
MDGL
Jul 30, 2026, 9:06 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $515.00
Real-time Price: $379.10 info
Change: -$135.90 (-26%) info
Market Cap: $8.806B info
MDGL
Jul 30, 2026, 7:15 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $533.00
Real-time Price: $379.10 info
Change: -$153.90 (-29%) info
Market Cap: $8.806B info
MDGL
Jul 30, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $533.00
Real-time Price: $379.10 info
Change: -$153.90 (-29%) info
Market Cap: $8.806B info
MDGL
Jul 13, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $534.50
Real-time Price: $379.10 info
Change: -$155.40 (-29%) info
Market Cap: $8.806B info
MDGL
Jul 01, 2026, 9:19 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $514.39
Real-time Price: $379.10 info
Change: -$135.29 (-26%) info
Market Cap: $8.806B info
MDGL
Jun 17, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $499.86
Real-time Price: $379.10 info
Change: -$120.76 (-24%) info
Market Cap: $8.806B info
MDGL
May 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $524.28
Real-time Price: $379.10 info
Change: -$145.18 (-28%) info
Market Cap: $8.806B info
MDGL
May 06, 2026, 9:04 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $514.69
Real-time Price: $379.10 info
Change: -$135.59 (-26%) info
Market Cap: $8.806B info
MDGL
May 06, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $503.01
Real-time Price: $379.10 info
Change: -$123.91 (-25%) info
Market Cap: $8.806B info
MDGL
May 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $503.01
Real-time Price: $379.10 info
Change: -$123.91 (-25%) info
Market Cap: $8.806B info
MDGL
May 05, 2026, 8:31 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $517.00
Real-time Price: $379.10 info
Change: -$137.90 (-27%) info
Market Cap: $8.806B info
MDGL
Apr 28, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $516.69
Real-time Price: $379.10 info
Change: -$137.59 (-27%) info
Market Cap: $8.806B info
MDGL
Feb 19, 2026, 9:09 AM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $448.38
Real-time Price: $379.10 info
Change: -$69.28 (-15%) info
Market Cap: $8.806B info
MDGL
Feb 19, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $451.00
Real-time Price: $379.10 info
Change: -$71.90 (-16%) info
Market Cap: $8.806B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets